Inotek Pharmaceuticals Corporation : Announces Publication of Phase 1 Data for Trabodenoson in Healthy Adult Volunteers in the Journal of Ocular Pharmacology and Therapeutics

Trabodenoson Safe, Well Tolerated and Resulted in No Dose-kin Ocular or Systemic Side Effects

Inotek Pharmaceuticals Corporation (the “Company” or “Inotek”) (NASDAQ: ITEK), a clinical-~-wagon biopharmaceutical company focused on the finding, development and commercialization of therapies with respect to ocular diseases, today announced the Journal of Ocular Pharmacology and Therapeutics (JOPT) has published the results from its Phase 1 dose-escalation trial in healthy adult volunteers of the Company’s precedence product candidate, trabodenoson. These results aid the ongoing clinical development of trabodenoson in the same proportion that a novel treatment for glaucoma, and come publication of the Phase 2 study in patients by primary open-angle glaucoma (POAG) or ocular hypertension (OHT), announced without interrupti~ April 11, 2016.

The research moment, “A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers,” presents facts showing that ocular doses of trabodenoson up to 3,200 µg per eye were safe and well tolerated one as well as the other in the eye and systemically in in good health adult volunteers. Trabodenoson is a fully-owned, first-in-class selective adenosine imitative designed to lower intraocular pressure (IOP) end its action at the trabecular meshwork (TM), the place of natural IOP regulation.

“Inotek continues to shape a compelling body of safety and force data for trabodenoson as a possible novel approach for the treatment of glaucoma,” before-mentioned Rudolf Baumgartner, M.D., Chief Medical Officer of Inotek. “Notably, the data from this multi-dose Phase 1 vexation showed no dose-related ocular or systemic faction effects even when administered at higher doses than those core evaluated in the ongoing Phase 3 distress, MATrX-1.”

“We believe the good-ocular tolerability of trabodenoson may lineage, in part, from its structural resemblance to naturally occurring adenosine. By activating the A1 adenosine receptor, and enhancing function of the intrinsic IOP regulating continuous experiment of the trabecular meshwork rather than changing the essential dynamics of pressure regulation in the fix the ~ on, we believe trabodenoson’s mechanism of representation carries a lower risk of unintended espouse a cause effects with long term chronic practice in patients with glaucoma,” commented William McVicar, Ph.D., Chief Scientific Officer of Inotek.

About the Phase 1 Study

The Phase 1 study was a randomized, double-masked, placebo-controlled draught escalation study designed to characterize the systemic and limited ocular safety and tolerability of trabodenoson delivered by way of topical ophthalmic dosing. Overall, 70 mature healthy volunteers were enrolled in this USA-based mortification. Key exclusion criteria included best-corrected of the eye acuity worse than 20/60 in one and the other eye, active eye disease and other factors.


ARTICLE REFERENCE: Journal of Ocular Pharmacology and Therapeutics. April 2016, onward of print. doi: 10.1089/jop.2015.0147. Study authors; Alan Laties1, Cadmus C. Rich2, Randall Stoltz3, Vernon Humbert4, Chaim Brickman2, William McVicar2, and Rudolf A. Baumgartner2.

1Scheie Eye Institute, Philadelphia, Pennsylvania.

2Inotek Pharmaceuticals Corporation, Lexington, Massachusetts.

3Covance Global Clinical Pharmacology, Evansville, Indiana.

4Evansville Heart Center, Evansville, Indiana.

About Inotek Pharmaceuticals Corporation

Inotek is a clinical-platform biopharmaceutical company focused on the ascertainment, development and commercialization of therapies towards glaucoma and other eye diseases. The Company’s serve product candidate, trabodenoson, is a in the beginning-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure ascendency mechanism. Additionally, the Company is evaluating the possible for selective adenosine mimetics to consign optic neuropathies and other degenerative retinal diseases. For else information, please visit The inclusion of our website solicitation here and elsewhere in this rush release does not include or blended by reference the information on our website into this enforce release.

Forward-Looking Statements

This force release contains forward-looking statements, what one. are subject to substantial risks, uncertainties and assumptions. These front-looking statements often include words in the same state as “believe,” “calculate upon,” “anticipate,” “intend,” “lay out,” “estimate,” “solicit,” “will,” “may” or similar expressions. Accordingly, you should not station undue reliance on these forward-looking statements. All like statements speak only as of the age made, and the Company undertakes not at all obligation to update or revise publicly some forward-looking statements, whether as a fruit of new information, future events or other causes.

View source version on

NBA TV takes a front back &#1072t th&#1077 &#1110n&#1089r&#1077&#1281&#1110b&#406&#1077 course &#959f 10-time NBA champion &#1072n&#1281 2007 Hall &#959f Fame inductee Phil Jackson.

Recent Comments